Does this seem outlandish?
Memantine for Diabetes ........
User Population:...... 800,000 ...... 1,200,000
Annual Tablets ............365..............365
SP per Tablet ...........$1.00............$1.00
Annual Rev $ ..........$365.00..........$365.00
Annual FRX Rev$ ..$292,000,000.....$438,000,000
NTII Royalty % ............15%...............15%
Royalties $ ......$43,800,000......$65,700,000
Opinions from anyone are greatly appreciated ....
Lastly, I view whatever the Royalties$ are as
equivalent to EBIT$ ...
other R&D being mgt./investor discretion
and G&A $ so small as to be ignored ....
regards,
John McCarthy |
